《bw》怎以读
00:00/00:00
《bw》是什么意思
Botswana 博茨瓦纳；
英英释义
bw
- n.the use of bacteria or viruses or toxins to destroy men and animals or food
同义词：biological warfarebiological attackbiologic attackbioattack
学习《bw》怎么用
权威例句
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropi...
Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic ...
DR Cox, DV Hinkley, N. Reid, DB Rubin and BW Silverman
Prediction of Intact Survival for Infants <33 Weeks Ga Based on Bw and Ga: a user Friendly Graphical Tool
Density Estimation for Statistics and Data Analysis
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
ACC/AHA 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary : A Report of the Ame...
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
The 2007 WHO classification of tumours of the central nervous system.
Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic ...
DR Cox, DV Hinkley, N. Reid, DB Rubin and BW Silverman
Prediction of Intact Survival for Infants <33 Weeks Ga Based on Bw and Ga: a user Friendly Graphical Tool
Density Estimation for Statistics and Data Analysis
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
ACC/AHA 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary : A Report of the Ame...
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
The 2007 WHO classification of tumours of the central nervous system.